Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1799 1
1801 1
1932 4
1934 1
1935 2
1936 1
1938 1
1941 1
1946 2
1947 3
1948 2
1949 1
1951 1
1954 1
1955 2
1956 3
1961 1
1962 1
1964 1
1965 1
1966 3
1968 4
1969 2
1970 3
1971 4
1972 3
1973 3
1974 4
1975 15
1976 27
1977 28
1978 17
1979 23
1980 29
1981 44
1982 51
1983 45
1984 65
1985 62
1986 77
1987 72
1988 84
1989 86
1990 103
1991 95
1992 113
1993 98
1994 97
1995 106
1996 101
1997 77
1998 96
1999 94
2000 123
2001 117
2002 114
2003 131
2004 168
2005 173
2006 208
2007 184
2008 197
2009 230
2010 255
2011 243
2012 257
2013 265
2014 261
2015 301
2016 258
2017 224
2018 250
2019 278
2020 272
2021 314
2022 266
2023 250
2024 87

Text availability

Article attribute

Article type

Publication date

Search Results

6,584 results

Results by year

Filters applied: . Clear all
Page 1
Targeting Huntingtin Expression in Patients with Huntington's Disease.
Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schobel SA, Paz E, Smith AV, Bennett CF, Lane RM; Phase 1–2a IONIS-HTTRx Study Site Teams. Tabrizi SJ, et al. Among authors: blair nf. N Engl J Med. 2019 Jun 13;380(24):2307-2316. doi: 10.1056/NEJMoa1900907. Epub 2019 May 6. N Engl J Med. 2019. PMID: 31059641 Clinical Trial.
BACKGROUND: Huntington's disease is an autosomal-dominant neurodegenerative disease caused by CAG trinucleotide repeat expansion in HTT, resulting in a mutant huntingtin protein. ...CONCLUSIONS: Intrathecal administration of HTT(Rx) to patients with early Huntington's …
BACKGROUND: Huntington's disease is an autosomal-dominant neurodegenerative disease caused by CAG trinucleotide repeat expansion in H …
Heparan Sulfate Proteoglycans in Tauopathy.
Zhu Y, Gandy L, Zhang F, Liu J, Wang C, Blair LJ, Linhardt RJ, Wang L. Zhu Y, et al. Among authors: blair lj. Biomolecules. 2022 Nov 30;12(12):1792. doi: 10.3390/biom12121792. Biomolecules. 2022. PMID: 36551220 Free PMC article. Review.
Tauopathies are a class of neurodegenerative diseases, including Alzheimer's disease, and are characterized by intraneuronal tau inclusion in the brain and the patient's cognitive decline with obscure pathogenesis. ...The heparan sulfate proteoglycans co-deposit wit …
Tauopathies are a class of neurodegenerative diseases, including Alzheimer's disease, and are characterized by intraneuronal tau incl …
Coccidioidomycosis.
Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA, Williams PL; Infectious Diseases Society of America. Galgiani JN, et al. Among authors: blair je. Clin Infect Dis. 2005 Nov 1;41(9):1217-23. doi: 10.1086/496991. Epub 2005 Sep 20. Clin Infect Dis. 2005. PMID: 16206093 Review. No abstract available.
Cyclooxygenase-2-mediated DNA damage.
Lee SH, Williams MV, Dubois RN, Blair IA. Lee SH, et al. Among authors: blair ia. J Biol Chem. 2005 Aug 5;280(31):28337-46. doi: 10.1074/jbc.M504178200. Epub 2005 Jun 17. J Biol Chem. 2005. PMID: 15964853 Free article.
Rat intestinal epithelial cells that express the cyclooxygenase-2 (COX-2) gene permanently (RIES cells) were used as a model of in vivo oxidative stress. A targeted lipidomics approach showed that 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE) was the major hydroxy …
Rat intestinal epithelial cells that express the cyclooxygenase-2 (COX-2) gene permanently (RIES cells) were used as a model of in vivo oxid …
Hexanic Extract of Serenoa repens (Permixon®): A Review in Symptomatic Benign Prostatic Hyperplasia.
Blair HA. Blair HA. Drugs Aging. 2022 Mar;39(3):235-243. doi: 10.1007/s40266-022-00924-3. Epub 2022 Mar 3. Drugs Aging. 2022. PMID: 35237936 Free PMC article. Review.
Thus, HE S. repens is a useful option for the treatment of symptomatic BPH. ...HE S. repens was generally well tolerated, and is a useful option for the treatment of symptomatic BPH....
Thus, HE S. repens is a useful option for the treatment of symptomatic BPH. ...HE S. repens was generally well tolerated, and …
Therapeutic Potential of the Hsp90/Cdc37 Interaction in Neurodegenerative Diseases.
Gracia L, Lora G, Blair LJ, Jinwal UK. Gracia L, et al. Among authors: blair lj. Front Neurosci. 2019 Nov 21;13:1263. doi: 10.3389/fnins.2019.01263. eCollection 2019. Front Neurosci. 2019. PMID: 31824256 Free PMC article. Review.
Alzheimer's, Huntington's, and Parkinson's are devastating neurodegenerative diseases that are prevalent in the aging population. ...
Alzheimer's, Huntington's, and Parkinson's are devastating neurodegenerative diseases that are prevalent in the aging p …
Neural grafting for Parkinson's disease: challenges and prospects.
Stoker TB, Blair NF, Barker RA. Stoker TB, et al. Among authors: blair nf. Neural Regen Res. 2017 Mar;12(3):389-392. doi: 10.4103/1673-5374.202935. Neural Regen Res. 2017. PMID: 28469646 Free PMC article. Review.
Parkinson's disease (PD) is a neurodegenerative condition which causes a characteristic movement disorder secondary to loss of dopaminergic neurons in the substanitia nigra. ...Dopaminergic neurons derived from embryonic stem cells offer the most promising basis for a cell …
Parkinson's disease (PD) is a neurodegenerative condition which causes a characteristic movement disorder secondary to loss of dopami …
Parkinson's disease in 1984: an update.
Lang AE, Blair RD. Lang AE, et al. Among authors: blair rd. Can Med Assoc J. 1984 Nov 1;131(9):1031-7. Can Med Assoc J. 1984. PMID: 6388779 Free PMC article. Review.
This update reviews several important topics in the field of Parkinson's disease, including etiologic studies, the types and mechanisms of drug complications and their treatment, when and how to begin treatment, the association of dementia with Parkinson's disease, …
This update reviews several important topics in the field of Parkinson's disease, including etiologic studies, the types and mechanis …
Dose of exercise and health benefits.
Blair SN, Cooper KH. Blair SN, et al. Arch Intern Med. 1997 Jan 27;157(2):153-4. Arch Intern Med. 1997. PMID: 9009971 No abstract available.
6,584 results